Caroline Seymour

For patients with hormone receptor-positive and HER2-low breast cancer, T-DXd elicited higher levels of PFS despite time to progression and disease burden.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

Regardless of high-risk features, brexucabtagene autoleucel demonstrated positive and durable responses in BTK-naive MCL.

For patients with relapsed/refractory large B-cell lymphoma, PFS and OS data from CD-19-directed, 4-1BB CAR T-cell Liso-cel therapy were consistent with prior results.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.

The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.

Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.

Durvalumab plus bevacizumab and TACE may be a new standard of care in unresectable hepatocellular carcinoma eligible for embolization, according to Riccardo Lencioni, MD.

DZD8586 results in favorable safety with limited grade 3 or greater treatment-emergent adverse effects in those with B-cell non-Hodgkin lymphoma, according to data from 2 ongoing phase 1 trials.

Data from the phase 3 PERSEUS trial supports D-VRd followed by DR maintenance as a new standard of care in patients with newly diagnosed, transplant-eligible multiple myeloma.

When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), as observed in the phase 3 FLAIR trial.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.

Patients with promyelocytic leukemia saw an improved overall survival and relapse-free survival when treated with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.

Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.

Treatment with BI 764532 produces a manageable safety profile among those with small cell lung cancer and neuroendocrine carcinoma in a phase 1 trial.

Treatment with zongertinib produces low rates of EGFR-mediated adverse effects among patients with HER2-mutated non–small cell lung cancer in the phase 1a/b BEAMION Lung-1 trial.

Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD

Investigators report no differences in rates of graft-versus-host-disease with intensive or non-intensive consolidation chemotherapy prior to transplantation for elderly patients with acute myeloid leukemia.

Eddy Saad, MD, explained how responses to immune checkpoint inhibitors can be elicited in patients with metastatic renal cell carcinoma.

In patients with metastatic renal cell carcinoma, neoadjuvant immunotherapy–based combinations yielded reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy.

Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.